A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
A putative tumor suppressor locus on the short arm of human chromosome 9 has been localized to a region of less than 40 kilobases by means of homozygous deletions in melanoma cell lines. This region contained a gene, Multiple Tumor Suppressor 1 (MTS1), that encodes a previously identified inhibitor (p16) of cyclin-dependent kinase 4. MTS1 was homozygously deleted at high frequency in cell lines derived from tumors of lung, breast, brain, bone, skin, bladder, kidney, ovary, and lymphocyte. Melanoma cell lines that carried at least one copy of MTS1 frequently carried nonsense, missense, or frameshift mutations in the gene. These findings suggest that MTS1 mutations are involved in tumor formation in a wide range of tissues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Within months of its discovery, the INK4a (CDKN2A) and the genetically linked INK4b gene (CDKN2B) (36) were implicated in a reverse genetic screen to play tumor suppressive roles in familial melanoma (37).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [37]
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
A novel cyclin encoded by a bcl1-linked candidate oncogene
Motokura, T., Bloom, T., Kim, H. G., Jüppner., H., Ruderman, J. V., Kronenberg, H. M., & Arnold, A. (1991) · Nature · doi:10.1038/350512a0 · Cited by 1,265
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit
Gu, Y., Turck, C. W., & Morgan, D. O. (1993) · Nature · doi:10.1038/366707a0 · Cited by 764
p53: At the Crossroads of Molecular Carcinogenesis and Risk Sssessment
Harris, C. C. (1993) · Science · doi:10.1126/science.8266092 · Cited by 475
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.
Rosenberg, C. L., Wong, E., Petty, E. M., Bale, A. E., Tsujimoto, Y., Harris, N. L., & Arnold, A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.21.9638 · Cited by 432
Research works printed but not linked: 1
- Weaver-Feldhaus, J., Proceedings of the National Academy of Sciences of the United States of America 91: 7563 (1994).
Cited by
Items 301–400 of 1,005
Molecular and Genetic Aspects of Lung Cancer
ROM, W. N., HAY, J. G., LEE, T. C., JIANG, Y., & TCHOU-WONG, K.-M. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.9908012 · Cited by 163
Schutte, M., da Costa, L. T., Hahn, S. A., Moskaluk, C., Hoque, A. T., Rozenblum, E., Weinstein, C. L., Bittner, M., Meltzer, P. S., & Trent, J. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.13.5950 · Cited by 163
The genome and epigenome of malignant melanoma
DAHL, C., & GULDBERG, P. (2007) · APMIS · doi:10.1111/j.1600-0463.2007.apm_855.xml.x · Cited by 162
Melanoma genetics: An update with focus on the CDKN2A(p16)/ARF tumor suppressors
Piepkorn, M. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.104687 · Cited by 162
Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia
Hatta, Y., Hirama, T., Miller, C., Yamada, Y., Tomonaga, M., & Koeffler, H. (1995) · Blood · doi:10.1182/blood.v85.10.2699.bloodjournal85102699 · Cited by 161
Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias
Ogawa, S., Hirano, N., Sato, N., Takahashi, T., Hangaishi, A., Tanaka, K., Kurokawa, M., Tanaka, T., Mitani, K., & Yazaki, Y. (1994) · Blood · doi:10.1182/blood.v84.8.2431.2431 · Cited by 161
Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications
Smith, J. (2000) · Frontiers in Bioscience · doi:10.2741/smith · Cited by 160
“In astrocytic gliomas one of the most freqeunt mechanisms of abrogating this control is through p16 inactivation which occurs in 33-68% of glioblastoma tumors and in 75-90% of glioblastoma-derived cell lines (98-104).”
BackgroundKim, K. S., Kimball, S. D., Misra, R. N., Rawlins, D. B., Hunt, J. T., Xiao, H.-Y., Lu, S., Qian, L., Han, W.-C., Shan, W., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0201520 · Cited by 157
Jin, X., Nguyen, D. M., Zhang, W. W., Kyritsis, A. P., & Roth, J. A. (1995) · PubMed · Cited by 179
Jarrard, D. F., Sarkar, S., Shi, Y., Yeager, T. R., Magrane, G., Kinoshita, H., Nassif, N., Meisner, L. F., Newton, M. A., Waldman, F. M., et al. (1999) · PubMed · Cited by 187
From centrocytic to mantle cell lymphoma: A clinicopathologic and molecular review of 3 decades
Swerdlow, S. H., & Williams, M. E. (2002) · Human Pathology · doi:10.1053/hupa.2002.30221 · Cited by 159
The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung
Beasley, M. B., Lantuéjoul, S., Abbondanzo, S. L., Chu, W., Hasleton, P. S., Travis, W. D., & Brambilla, E. (2003) · Human Pathology · doi:10.1053/hupa.2003.8 · Cited by 158
The Senescence Markers p16INK4A, p14ARF/p19ARF, and p21 in Organ Development and Homeostasis
Wagner, K.-D., & Wagner, N. (2022) · Cells · doi:10.3390/cells11121966 · Cited by 156
“p16INK4A was originally identified as a tumor suppressor gene [42,43].”
BackgroundAnsari-Lari, M. A., Staebler, A., Zaino, R. J., Shah, K. V., & Ronnett, B. M. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200402000-00002 · Cited by 158
The genetics of pancreatic cancer
Cowgill, S. M., & Muscarella, P. (2003) · The American Journal of Surgery · doi:10.1016/s0002-9610(03)00226-5 · Cited by 180
Huschtscha, L. I., Noble, J. R., Neumann, A. A., Moy, E. L., Barry, P. A., Melki, J. R., Clark, S. J., & Reddel, R. R. (1998) · PubMed · Cited by 186
Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile.
Wistuba, I. I., Sugio, K., Hung, J. Y., Kishimoto, Y., Virmani, A. K., Roa, I., Albores‐Saavedra, J., & Gazdar, A. F. (1995) · PubMed · Cited by 155
Illei, P. B., Ladanyi, M., Rusch, V. W., & Zakowski, M. F. (2002) · Cancer · doi:10.1002/cncr.10923 · Cited by 155
Carcinogenesis in mouse and human cells: parallels and paradoxes
Balmain, A., & C.Harris, C. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.371 · Cited by 155
Cellular Response to Oncogenic Ras Involves Induction of the Cdk4 and Cdk6 Inhibitor p15INK4b
Malumbres, M., Pérez De Castro, I., Hernández, M. I., Jiménez, M., Corral, T., & Pellicer, A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2915-2925.2000 · Cited by 153
“Both loci, INK4a and INK4b, are frequently deleted in a variety of tumors and cell lines ( 22 , 58).”
BackgroundMolecular genetics of familial cutaneous melanoma.
Haluska, F. G., & Hodi, F. S. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.670 · Cited by 154
Kaye, F. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205834 · Cited by 153
“The almost simultaneous description of the p16 gene as the locus conferring susceptibility familial melanoma (Kamb et al., 1994), as a common site for homozygous deletions in tumor cell lines (Kamb et al., 1994), and as a negative regulator for the CDK4/6 kinase (Serrano et al., 1993) which…”
BackgroundMolecular biology of esophageal squamous cell carcinoma
Lam, A. K.-Y. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00054-2 · Cited by 176
Chemoprevention of digestive organs carcinogenesis by natural product protocatechuic acid
Tanaka, T., Kojima, T., Kawamori, T., & Mori, H. (1995) · Cancer · doi:10.1002/1097-0142(19950315)75:6+<1472::aid-cncr2820751515>3.0.co;2-8 · Cited by 79
Platz, A., Hansson, J., Mansson-Brahme, E., Lagerlof, B., Linder, S., Ringborg, U., Lundqvist, E., Sevigny, P., & Inganas, M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.10.697 · Cited by 154
“Exon 1 was sequenced with the primer combinations of Kamb et al. ( 8 ).”
BackgroundMethodInfluentialMansour, J. C., & Chen, H. (2004) · Journal of Surgical Research · doi:10.1016/j.jss.2003.12.007 · Cited by 164
Genetic Epidemiology of Cutaneous Melanoma: A Global Perspective
Goldstein, A. M., & Tucker, M. A. (2001) · Archives of Dermatology · doi:10.1001/archderm.137.11.1493 · Cited by 183
Reynolds, S. E., Billett, M. A., Gordon, C., Colleaux, L., Kloetzel, P. M., Tanaka, K., Dawson, S. P., Arnold, J. E., Mayer, N. J., & Mayer, R. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.4.1850 · Cited by 152
Overcoming cellular senescence in human cancer pathogenesis
Yeager, T. R., DeVries, S., Jarrard, D. F., Kao, C., Nakada, S. Y., Moon, T. D., Bruskewitz, R., Stadler, W. M., Meisner, L. F., Gilchrist, K. W., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.163 · Cited by 152
“Furthermore, a higher percentage of these mutations were observed in TCC cell lines than in uncultured tumors (Kamb et al. 1994).”
BackgroundPrognostic Significance of p16 Protein Levels in Oropharyngeal Squamous Cell Cancer
Weinberger, P., Yu, Z., Haffty, B. G., Kowalski, D. P., Harigopal, M., Sasaki, C. T., Rimm, D. L., & Psyrri, A. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0448 · Cited by 151
A gene for familial venous malformations maps to chromosome 9p in a second large kindred.
Gallione, C. J., Pasyk, K. A., Boon, L. M., Lennon, F., Johnson, D. W., Helmbold, E. A., Markel, D. S., Vikkula, M., Mulliken, J. B., & Warman, M. L. (1995) · Journal of Medical Genetics · doi:10.1136/jmg.32.3.197 · Cited by 159
Tien, H., Tang, J., Tsay, W., Liu, M., Lee, F., Wang, C., Chen, Y., & Shen, M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02496.x · Cited by 160
“Inactivation of the p15INK4B and p16INK4A genes by homozygous deletion has been detected in many cancers, suggesting that they are candidate tumour suppressor genes (Kamb et al, 1994; Nobori et al, 1994).”
BackgroundCalifano, J. A., Westra, W. H., Koch, W. M., Meininger, G., Reed, A., Yip, L., Boyle, J. O., Lonardo, F., & Sidransky, D. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.599 · Cited by 159
Promoter-Region Hypermethylation and Gene Silencing in Human Cancer
Herman, J. G., & Baylin, S. B. (2000) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-59696-4_3 · Cited by 157
Prognostic factors in gastric cancer
Allgayer, H., Heiss, M. M., & Schildberg, F. W. (1997) · British journal of surgery · doi:10.1002/bjs.1800841206 · Cited by 167
Christopher, S. A., Diegelman, P., Porter, C. W., & Kruger, W. D. (2002) · PubMed · Cited by 167
Brune, K. A., & Klein, A. P. (2008) · Springer eBooks · doi:10.1007/978-0-387-69252-4_5 · Cited by 150
p53 GENE MUTATIONS AND PHOTOCARCINOGENESIS
Nataraj, A. J., Trent, J. C., & Ananthaswamy, H. N. (1995) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1995.tb05262.x · Cited by 167
Walker, G. J., Flores, J. F., Glendening, J. M., Lin, A. H., Markl, I. D. C., & Fountain, J. W. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199806)22:2<157::aid-gcc11>3.0.co;2-n · Cited by 161
Takeuchi, S., Bartram, C., Seriu, T., Cw, M., Tobler, A., Janssen, J. W. G., Reiter, A., Ludwig, W., Zimmermann, M., & Schwaller, J. (1995) · Blood · doi:10.1182/blood.v86.2.755.bloodjournal862755 · Cited by 156
Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape
Sekulic, A., Haluska, P., Miller, A. J., De Lamo, J. G., Ejadi, S., Pulido, J. S., Salomao, D. R., Thorland, E. C., Vile, R. G., Swanson, D. L., et al. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.7.825 · Cited by 148
Molecular Biology of Head and Neck Cancer
Lam, D. K., & Schmidt, B. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-2527-6.00010-4 · Cited by 155
Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control
Oelgeschläger, T. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10058 · Cited by 169
“INK4 proteins (inhibitors of CDK4 and CDK6) can directly block cyclin D-dependent kinase activity, causing cells to arrest in G1 phase (Serrano et al., 1993; Guan et al., 1994; Hannon and Beach, 1994; Kamb et al., 1994; Nobori et al., 1994; Chan et al., 1995; Hirai et al., 1995; Sherr, 1996).”
BackgroundHigh Prognostic Value of p16INK4 Alterations in Gastrointestinal Stromal Tumors
Schneider‐Stock, R., Boltze, C., Lasota, J. P., Miettinen, M., Peters, B., Pross, M., Roessner, A., & Günther, T. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.101 · Cited by 147
Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma.
van der Velden, P. A., Metzelaar-Blok, J. A. W., Bergman, W., Monique, H., Hurks, H. M. H., Frants, R. R., Gruis, N. A., & Jager, M. J. (2001) · PubMed · Cited by 174
Batova, A., Diccianni, M. B., Yu, J., Nobori, T., Link, M. P., Pullen, J., & Yu, A. L.-T. (1997) · PubMed · Cited by 164
Splicing into Senescence: The Curious Case of p16 and p19ARF
Haber, D. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80441-9 · Cited by 158
“Within the minimal deleted region lay p16 (Kamb et al., 1994), previously identified by virtue of the interaction of its encoded protein with the cyclin-dependent kinase 4 (CDK4) (Serrano et al., 1993).”
BackgroundMolecular mechanisms of photocarcinogenesis
Matsumura, Y. (2002) · Frontiers in Bioscience · doi:10.2741/matsumur · Cited by 143
Singh, R. K., Gutman, M., Reich, R., & Bar‐Eli, M. (1995) · PubMed · Cited by 166
Sonoda, I., Imoto, I., Inoue, J., Shibata, T., Shimada, Y., Chin, K., Imamura, M., Amagasa, T., Gray, J. W., Hirohashi, S., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0172 · Cited by 144
The genetics of hereditary melanoma and nevi: 1998 Update
Greene, M. H. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991201)86:11+<2464::aid-cncr3>3.0.co;2-f · Cited by 144
Cyclin-Dependent Kinase Regulation during G1 Phase and Cell Cycle Regulation by TGF-ß
Ravitz, M. J., & Wenner, C. E. (1997) · Advances in cancer research · doi:10.1016/s0065-230x(08)60099-8 · Cited by 168
Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
Dreyling, M. H., Bullinger, L., Ott, G., Stilgenbauer, S., Müller-Hermelink, H. K., Bentz, M., Hiddemann, W., & Döhner, H. (1997) · PubMed · Cited by 144
Santos, M., Montagut, C. O., Mellado, B., García, Á., y Cajal, S. R., Cardesa, A., Puig-Tintoré, L. M., & Ordï, J. (2004) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000130108.03231.89 · Cited by 143
The INK4 Family of CDK Inhibitors
Carnero, A., & Hannon, G. J. (1998) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-71941-7_3 · Cited by 189
Frequent Aberrant Methylation of p16INK4a in Primary Rat Lung Tumors
Swafford, D. S., Middleton, S. K., Palmisano, W. A., Nikula, K. J., Tesfaigzi, J., Baylin, S. B., Herman, J. G., & Belinsky, S. A. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1366 · Cited by 142
Zou, X., Ray, D., Aziyu, A., Christov, K., Boiko, A. D., Gudkov, A. V., & Kiyokawa, H. (2002) · Genes & Development · doi:10.1101/gad.1033002 · Cited by 142
“More frequent cancer-associated alterations are deletions, mutations, and methylation of the Ink4a/Arf locus (Kamb et al. 1994; Sherr 1998; Sharpless and DePinho 1999).”
BackgroundProinvasion Metastasis Drivers in Early-Stage Melanoma Are Oncogenes
Scott, K. L., Nogueira, C., Heffernan, T. P., van Doorn, R., Dhakal, S., Hanna, J. A., Min, C., Jaskelioff, M., Xiao, Y., Wu, C.-J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.025 · Cited by 141
“Given the frequency and demonstrated relevance of INK4A/ARF deletions in melanoma (Hussussian et al., 1994; Kamb et al., 1994), these compound transgenic alleles were further intercrossed onto an INK4A/ARF null background to generate cohorts of single- and double-transgenic mice (designated iMet)…”
The role of cell cycle regulatory proteins in the pathogenesis of melanoma
Li, W., Sanki, A., Karim, R. Z., Thompson, J. F., Lee, C. S., Zhuang, L., McCarthy, S. W., & Scolyer, R. A. (2006) · Pathology · doi:10.1080/00313020600817951 · Cited by 158
Germline Mutations of the CDKN2 Gene in UK Melanoma Families
Harland, M., Meloni, R., Gruis, N., Pinney, E., Brookes, S., Spurr, N. K., Frischauf, A.-M., Bataille, V., Peters, G., Cuzick, J., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.12.2061 · Cited by 142
Cellular effects of olomoucine, an inhibitor of cyclin‐dependent kinases
Abraham, R., Acquarone, M., Andersen, A., Asensi, A., Bellé, R., Berger, F., Bergounioux, C., Brunn, G., Buquet‐Fagot, C., Fagot, D., et al. (1995) · Biology of the Cell · doi:10.1016/0248-4900(96)81298-6 · Cited by 140
Molecular biology of normal melanocytes and melanoma cells
Bandarchi, B., Jabbari, C., Vedadi, A., & Navab, R. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201471 · Cited by 160
Thompson, F. H., Emerson, J., Olson, S., Weinstein, R. S., Leavitt, S. A., Leong, S. P. L., Emerson, S. S., Trent, J. M., Nelson, M. A., Salmon, S. E., et al. (1995) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(95)00057-v · Cited by 138
Papp, T., Pemsel, H., Zimmermann, R., Bastrop, R., Weiss, D. G., & Schiffmann, D. (1999) · Journal of Medical Genetics · doi:10.1136/jmg.36.8.610 · Cited by 139
Molecular Pathogenesis of Cutaneous Melanocytic Neoplasms
Ibrahim, N., & Haluska, F. G. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.151541 · Cited by 138
Rady, P. L., Schnadig, V. J., Weiss, R. L., Hughes, T. K., & Tyring, S. K. (1998) · The Laryngoscope · doi:10.1097/00005537-199805000-00021 · Cited by 138
Crystal Structure of a Human Cyclin-Dependent Kinase 6 Complex with a Flavonol Inhibitor, Fisetin
Lu, H., Chang, D. J., Baratte, B., Meijer, L., & Schulze-Gahmen, U. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049353p · Cited by 147
Yang, R., Roberta Morosetti, A., & Koeffler, H. P. (1997) · PubMed · Cited by 143
p16 gene alterations in nasopharyngeal carcinoma.
Lo, K. W., Huang, D. P., & Lau, K. (1995) · PubMed · Cited by 149
Overexpression of ANXA1 in Penile Carcinomas Positive for High-Risk HPVs
Calmon, M. F., Mota, M. T. D. O., Babeto, É., Candido, N. M., Girol, A. P., Mendiburu, C. F., Bonilha, J. L., Silvestre, R. V. D., Rosa, B. M., Thomé, J. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053260 · Cited by 136
Chung, D. C., Smith, A. P., Louis, D. N., Graeme‐Cook, F., Warshaw, A. L., & Arnold, A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119547 · Cited by 137
Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma.
Flores, J. F., Walker, G. J., Glendening, J. M., Haluska, F. G., Castresana, J. S., Rubio, M., Pastorfide, G. C., Boyer, L. A., Kao, W. H., Bulyk, M. L., et al. (1996) · PubMed · Cited by 169
Oncogenic potential of the DNA replication licensing protein CDT1
Arentson, E., Faloon, P. W., Seo, J., Moon, E., Studts, J., Fremont, D. H., & Choi, K. (2002) · Oncogene · doi:10.1038/sj.onc.1205175 · Cited by 149
“Cyclin D1 is overexpressed in many cancers (Motokura et al., 1991) and INK4a is inactivated in familial melanoma, biliary tract, and esophageal carcinomas (Kamb et al., 1994; Nobori et al., 1994).”
BackgroundNeßling, M., Richter, K., Schwäenen, C., Roerig, P., Wrobel, G., Weßendorf, S., Fritz, B., Bentz, M., Sinn, H., Radlwimmer, B., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.439.65.2 · Cited by 134
“(45) the BAC clone RP11-149I2 on 9p21 was tested positive for the tumor suppressor genes CDKN2A (p16) and CDKN2B (p15).”
BackgroundHruban, R. H., Petersen, G. M., Goggins, M., Tersmette, A. C., Offerhaus, G. J. A., Falatko, F., Yeo, C. J., & Kern, S. E. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_4.s69 · Cited by 134
Molecular biology of gastric cancer
Tahara, E. (1995) · World Journal of Surgery · doi:10.1007/bf00294705 · Cited by 133
“MTS1 encodes p16 protein, which binds to CDK4 and inhibits the catalytic activity of the CDK4/cyclin D enzyme [ 24 ].”
BackgroundKumar, S., Park, S. H., Cieply, B., Schupp, J., Killiam, E., Zhang, F., Rimm, D. L., & Frisch, S. M. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01342-10 · Cited by 134
Methylation and colorectal cancer
Jubb, A. M., Bell, S. M., & Quirke, P. (2001) · The Journal of Pathology · doi:10.1002/path.923 · Cited by 142
Deletions of the INK4A Gene in Superficial Bladder Tumors
Orlow, I., LaRue, H., Osman, I., Lacombe, L., Moore, L., Rabbani, F., Meyer, F., Fradet, Y., & Cordon‐Cardo, C. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65105-x · Cited by 147
The Retinoblastoma Gene: A Prototypic and Multifunctional Tumor Suppressor
Zheng, L., & Lee, W. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5129 · Cited by 157
p16 gene homozygous deletions in acute lymphoblastic leukemia
Quesnel, B., Preudhomme, C., Philippe, N., Vanrumbeke, M., Dervite, I., Lai, J., Bauters, F., Wattel, E., & Fenaux, P. (1995) · Blood · doi:10.1182/blood.v85.3.657.bloodjournal853657 · Cited by 133
Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients
Silva, J. M., Dominguez, G., Villanueva, M. J., Gonzalez, R., Garcia, J. M., Corbacho, C., Provencio, M., España, P., & Bonilla, F. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690495 · Cited by 132
“The p16INK4a gene was found to be inactivated in a la percentage of tumour cell lines (Kamb et al, 1994; Nobori e 1994; Okamoto et al, 1994).”
BackgroundYoshida, J., Mizuno, M., Fujii, M., Kajita, Y., Nakahara, N., Hatano, M., Saito, R., Nobayashi, M., & Wakabayashi, T. (2004) · Human Gene Therapy · doi:10.1089/10430340460732472 · Cited by 131
Slominski, A. T., Wortsman, J., Carlson, A. J., Matsuoka, L. Y., Balch, C. M., & Mihm, M. C. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-1295-mm · Cited by 136
Mechanisms Involved in Ultraviolet Light-Induced Immunosuppression
Beissert, S., & Schwarz, T. (1999) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/sj.jidsp.5640183 · Cited by 142
Deregulation of the Rb and p53 Pathways in Uveal Melanoma
Brantley, M. A., & Harbour, J. W. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64817-1 · Cited by 131
Myc oncogene: a key component in cell cycle regulation and its implication for lung cancer
Zajac‐Kaye, M. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00343-9 · Cited by 155
Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer
Belinsky, S. A. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi020 · Cited by 148
Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia
Guo, S.-X., Taki, T., Ohnishi, H., Piao, H., Tabuchi, K., Bessho, F., Hanada, R., Yanagisawa, M., & Hayashi, Y. (2000) · Leukemia Research · doi:10.1016/s0145-2126(99)00158-7 · Cited by 137
Govindarajan, B., Bai, X., Cohen, C., Zhong, H., Kilroy, S. M., Louis, G. W., Moses, M. A., & Arbiser, J. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212929200 · Cited by 130
Familial melanoma, pancreatic cancer and germline CDKN2A mutations
Goldstein, A. M. (2004) · Human Mutation · doi:10.1002/humu.9247 · Cited by 130
“The CDKN2A (MIM# 600160) gene, located on chromosome 9p21 (Kamb et al., 1994; Nobori et al., 1994), is the major high-risk melanoma susceptibility gene identified to date.”
BackgroundMethylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma.
El‐Naggar, A. K., Lai, S., Clayman, G. L., Lee, J. K., Luna, M. A., Goepfert, H., & Batsakis, J. G. (1997) · Europe PMC (PubMed Central) · Cited by 129
Xia, Y.-P., Zhao, Y., Marcus, J., Jimenez, P. A., Ruben, S. M., Moore, P. A., Khan, F., & Mustoe, T. A. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199908)188:4<431::aid-path362>3.0.co;2-b · Cited by 129
Franklin, D. S., & Xiong, Y. (1996) · Molecular Biology of the Cell · doi:10.1091/mbc.7.10.1587 · Cited by 128
A Structure-Based Library Approach to Kinase Inhibitors
Norman, T., Gray, N. S., Koh, J. T., & Schultz, P. G. (1996) · Journal of the American Chemical Society · doi:10.1021/ja9614934 · Cited by 133
Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T- cell leukemia/lymphoma
Roberta Morosetti, A., Kawamata, N., Gombart, A., Cw, M., Hatta, Y., Hirama, T., Jw, S., Tomonaga, M., & Koeffler, H. (1995) · Blood · doi:10.1182/blood.v86.5.1924.bloodjournal8651924 · Cited by 134
Reznikoff, C. A., Belair, C., Savelieva, E., Zhai, Y., Pfeifer, K., Yeager, T., Thompson, K. J., DeVries, S., Bindley, C., & Newton, M. A. (1994) · Genes & Development · doi:10.1101/gad.8.18.2227 · Cited by 129
Mitochondrial p32 Is a Critical Mediator of ARF-Induced Apoptosis
Itahana, K., & Zhang, Y. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.002 · Cited by 145
Czerniak, B. A., Chaturvedi, V., Li, L., Hodges, S., Johnston, D. A., Ro, J. Y., Luthra, R., Logothetis, C. J., von Eschenbach, A. C., Grossman, H. B., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202385 · Cited by 127
“An area corresponding to 9p21-22 is of particular interest, as the putative tumor suppressor genes (MTS 1 and 2) were mapped to this region (Kamb et al., 1994).”
Doria, A. (2008) · JAMA · doi:10.1001/jama.2008.649 · Cited by 127
Metadata
- Authors
- Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H.
- Affiliations
- Myriad Genetics (US)
- Memorial Sloan Kettering Cancer Center (US)
- Cross Cancer Institute (CA)
- National Institutes of Health (US)
- University of Utah (US)
- Venue
- Science
- Published
- 1994-04-15
- Volume
- 264
- Issue
- 5157
- Pages
- 436-440
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1983348452
- Cited by
- 2,751
- References
- 26
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 18 · 2023: 12 · 2022: 22 · 2021: 31 · 2020: 24 · 2019: 23 · 2018: 34 · 2017: 45 · 2016: 20 · 2015: 32 · 2014: 31 · 2013: 44 · 2012: 54
- FWCI
- 115.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ca048711-05)
- National Cancer Institute (CA 48711)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDKN2A, p16, tumor suppressor, chromosome 9p, homozygous deletion, melanoma cell lines, CDK4, cell cycle regulation, genetic mutations
- MeSH terms
- Base Sequence, Carrier Proteins, Cell Cycle, Chromosomes, Human, Pair 9, Cosmids, Exons, Humans, Introns, Melanoma, Molecular Sequence Data, Mutation, Neoplasms, Proto-Oncogene Proteins, Tumor Cells, Cultured, Genes, Tumor Suppressor, Gene Deletion, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.